Activation and selectivity of OTUB-1 and OTUB-2 deubiquitinylases
Dakshinamurthy Sivakumar1, Vikash Kumar1,2, Michael Naumann2
1Max Planck Institute for Dynamics of Complex Technical Systems, Molecular Simulations and Design Group, 39106 Magdeburg, Germany.
Abstract:
The ovarian tumor domain (OTU) deubiquitinylating cysteine proteases OTUB1 and OTUB2 (OTU ubiquitin aldehyde binding 1 and 2) are representative members of the OTU subfamily of deubiquitinylases. Deubiquitinylation critically regulates a multitude of important cellular processes, such as apoptosis, cell signaling, and growth. Moreover, elevated OTUB expression has been observed in various cancers, including glioma, endometrial cancer, ovarian cancer, and breast cancer. Here, using molecular dynamics simulation approaches, we found that both OTUB1 and OTUB2 display a catalytic triad characteristic of proteases but differ in their configuration and protonation states. The OTUB1 protein had a prearranged catalytic site, with strong electrostatic interactions between the active-site residues His265 and Asp267 In OTUB2, however, the arrangement of the catalytic triad was different. In the absence of ubiquitin, the neutral states of the catalytic-site residues in OTUB2 were more stable, resulting in larger distances between these residues. Only upon ubiquitin binding did the catalytic triad in OTUB2 rearrange and bring the active site into a catalytically feasible state. An analysis of water access channels revealed only a few diffusion trajectories for the catalytically active form of OTUB1, whereas in OTUB2 the catalytic site was solvent-accessible, and a larger number of water molecules reached and left the binding pocket. Interestingly, in OTUB2, the catalytic residues His224 and Asn226 formed a stable hydrogen bond. We propose that the observed differences in activation kinetics, protonation states, water channels, and active-site accessibility between OTUB1 and OTUB2 may be relevant for the selective design of OTU inhibitors.
Insights
Ovarian tumor domain deubiquitinylating enzymes OTUB1 and OTUB2 show distinct catalytic site configurations and water accessibility. These differences in ovarian tumor domain ubiquitin aldehyde binding 1 and 2 may guide selective inhibitor design for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Ovarian tumor domain (OTU) deubiquitinylating proteases, specifically OTUB1 and OTUB2, are key regulators of cellular processes like apoptosis and signaling.
- Elevated expression of OTUB proteins is linked to various cancers, including ovarian, breast, and endometrial cancers, highlighting their oncogenic potential.
Purpose of the Study:
- To investigate the structural and dynamic differences between OTUB1 and OTUB2 using molecular dynamics simulations.
- To elucidate the mechanisms underlying the catalytic activity and substrate accessibility of OTUB1 and OTUB2.
- To identify potential targets for the selective design of OTU-based inhibitors for cancer treatment.
Main Methods:
- Molecular dynamics (MD) simulations were employed to analyze the catalytic triad configuration, protonation states, and water accessibility of OTUB1 and OTUB2.
- Analysis of active-site residue interactions and water diffusion trajectories was performed.
Main Results:
- Both OTUB1 and OTUB2 possess a catalytic triad characteristic of proteases, but with distinct configurations and protonation states.
- OTUB1 features a prearranged catalytic site, while OTUB2 requires ubiquitin binding for catalytic triad rearrangement into an active conformation.
- OTUB2 exhibits greater solvent accessibility to its catalytic site compared to OTUB1, with a stable hydrogen bond between His224 and Asn226.
Conclusions:
- The observed differences in activation kinetics, protonation states, water channels, and active-site accessibility between OTUB1 and OTUB2 are significant.
- These mechanistic distinctions provide a basis for the rational and selective design of OTU inhibitors targeting specific deubiquitinylases in cancer therapy.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
09:45Method for Measuring the Activity of Deubiquitinating Enzymes in Cell Lines and Tissue Samples
Published on: May 10, 2015
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome Structure
The proteasome is an...
Export of Misfolded Proteins out of the ER
